Genmab (NASDAQ:GMAB) 주식

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) has outperformed the market over the past 5 years by 24.11% on an annualized basis producing an average annual return of 44.38%. Currently, Fluor has a market capitalization of $6.25 billion. 
Buying $1000 In FLR: If an investor had bought $1000 of FLR stock 5 years ago, it would be worth $6,607.46 today based on a price of $37.20 for FLR at the time of writing.
<h3>Fluor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742339754_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Fluor 5 Years Ago Would Be Worth Today

Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has outperformed the market over the past 10 years by 10.59% on an annualized basis producing an average annual return of 20.98%. Currently, Apple has a market capitalization of $3.19 trillion. 
Buying $100 In AAPL: If an investor had bought $100 of AAPL stock 10 years ago, it would be worth $668.78 today based on a price of $212.60 for AAPL at the time of writing.
<h3>Apple's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742337922_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Apple Stock In The Last 10 Years

SMCI

Supermicro Unveils New Systems And Rack Solutions Powered By Nvidia's Blackwell Ultra Platform

Shopify expects that its Class A Subordinate Voting Shares will cease trading on the NYSE at market close on Friday, March 28, 2025 and that its Class A Subordinate Voting Shares will commence trading on the Nasdaq on Monday, March 31, 2025.

SHOP

Shopify To Voluntarily Transfer Its US Stock Exchange Listing To Nasdaq From NYSE

Guidance

ZTO Expects 2025 Parcel Volume Of 40.8B - 42.2B, Representing 20% - 24% Increase YoY

Earnings

ZTO Express (Cayman) Q4 Adj EPADS $0.44 Misses $0.46 Estimate, Sales $1.77B Beat $1.66B Estimate

NVDA REVERSES EARLY DECLINE ON SIGNAL
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="550" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/18195211/Screen-Shot-2025-03-18-at-3.51.13-PM-1024x550.png" alt="" class="wp-image-8230" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/18195211/Screen-Shot-2025-03-18-at-3.51.13-PM-1024x550.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/18195211/Screen-Shot-2025-03-18-at-3.51.13-PM-300x161.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/18195211/Screen-Shot-2025-03-18-at-3.51.13-PM-768x412.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/18195211/Screen-Shot-2025-03-18-at-3.51.13-PM.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Nvidia , Inc. (NVDA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:11 AM on March 18th, a significant trading signal occurred for Nvidia, Inc. (NVDA) as it demonstrated a Power Inflow at a price of $115.07. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Nvdia&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Nvdia&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for NVDA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $115.07. The returns on the High price ($119.03) and Close price ($115.43) after the Power Inflow were respectively 3.4% and 0.3%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Performance is Not Indicative of Future Results

Technicals

Signals

Markets

NVDA

Nvidia Shares up Over 3% After Key Signal, Reversing Early Decline

LexinFintech Expects 2025 Total Loan Origination To Have Flat To Single-digit YoY Growth Depending On Macroeconomic Conditions, Alongside Significant Increase In Net Income

LexinFintech Q4 EPADS $0.28, Total Operating Revenue $501.259M

<a href="https://europeancapitalinsights.substack.com/p/german-parliament-backs-changes-to?r=3nmatg">Germany's parliament backed </a>on Tuesday a plan to increase government borrowing limits as the largest economy in Europe looks to bolster its defense and infrastructure spending.
The Bundestag approved <a href="https://x.com/eurocapinsights">several amendments</a> to the country&#8217;s constitution, allowing future federal and state governments to take on more debt. This will enable higher defense spend and €500 billion for infrastructure to bolster the European Union's (EU) military capabilities.
German Chancellor-in-waiting Friedrich Merz proposed defense spending as the EU grows increasingly concerned about the US commitment to Europe's security. President Donald Trump <a href="https://x.com/eurocapinsights/status/1902097767855796426">has criticized European</a> nations for not meeting their NATO commitment of <a href="https://www.nato.int/cps/en/natohq/topics_49198.htm" target="_blank" rel="noreferrer noopener">2% of GDP</a> per year by 2024, threatening to reassess the US commitment to the military alliance.
&#8220;We have for at least a decade felt a false sense of security,&#8221; Merz <a href="https://www.reuters.com/business/aerospace-defense/merz-sees-new-era-european-defence-with-german-spending-surge-2025-03-18/" target="_blank" rel="noreferrer noopener">told</a> the Bundestag lower house of parliament on Tuesday. "The post-war peace dividend had been used up long ago and a total rebuilding of Germany&#8217;s defense capabilities was needed," he added.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc4695a40-182f-47ee-a596-893066a6c178_622x387.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc4695a40-182f-47ee-a596-893066a6c178_622x387.png" alt="" /></a><figcaption class="wp-element-caption">Source:<a target="_blank" rel="noreferrer noopener" href="https://x.com/MichaelAArouet/status/1901544764081680698"> X</a></figcaption></figure>
In an interview with public broadcaster ARD on Sunday, Merz <a target="_blank" rel="noreferrer noopener" href="https://thedefensepost.com/2025/03/18/germany-defense-spending/">said </a>the "situation has worsened in recent weeks." He cited Trump's overtures to Russia to end the Ukraine war and his wavering commitment to NATO.
"That is why we have to act fast," Merz said. He has urged an amendment to the constitution to exempt defense spending beyond <a target="_blank" rel="noreferrer noopener" href="https://europeancapitalinsights.substack.com/p/europes-ambitious-defense-plans-face">1% of GDP.</a>
<h2 class="wp-block-heading">German Decisions Push European Markets Higher</h2>
The pan-European Stoxx 600 closed 0.61% higher on Tuesday, with most sectors and all major bourses in positive territory. Frankfurt's DAX German corporates Rheinmetall, Bayer, ThyssenKrupp, and Continental traded higher on the news.
DAX is up 16.76% year-to-date, outperforming its American counterpart, the S&amp;P 500, by over 20%.
<a target="_blank" rel="noreferrer noopener" href="https://www.dw.com/en/germanys-bundestag-votes-in-favor-of-reforming-debt-brake/live-71956815">Some 513 parliamentary </a>members voted in favor of the constitutional changes, while 207 voted against them. Over two-thirds of parliament members needed to vote to change Germany&#8217;s basic law to soften the debt brake.
The decision to increase public investment and relax constitutionally enshrined borrowing rules to allow higher defense spending "sends a very clear message to Europe that Germany is determined to invest massively in defense,&#8221; EU Commission President <a target="_blank" rel="noreferrer noopener" href="https://www.dw.com/en/ursula-von-der-leyen/t-70279537">Ursula von der Leyen</a> said.
The center-right bloc of the Christian Democratic Union (CDU) and Christian Social Union (CSU), along with the center-left Social Democrats (SPD) and the Greens, supported the package.
The Bundesrat, a body representing the country's states, will meet on Friday to vote on the law. Only then will it become enshrined in Germany's constitution.
<h2 class="wp-block-heading">German Economy Constrained by ‘Debt Brake'</h2>
German government spending has <a target="_blank" rel="noreferrer noopener" href="https://europeancapitalinsights.substack.com/p/europes-ambitious-defense-plans-face">historically been constrained</a> by its "debt brake." The limits have restricted new annual borrowing to 0.35% of total GDP. If Germany amends its constitution, it will allow the government to borrow <a target="_blank" rel="noreferrer noopener" href="https://www.euronews.com/business/2025/03/05/germany-to-ease-government-debt-limits-to-boost-economy-and-defence-spending">over </a>€1<a target="_blank" rel="noreferrer noopener" href="https://www.euronews.com/business/2025/03/05/germany-to-ease-government-debt-limits-to-boost-economy-and-defence-spending"> trillion </a>over the next decade.
"The next federal government will have little choice but to make massive public investments in defense capabilities," Deutsche Bank Research Institute <a target="_blank" rel="noreferrer noopener" href="https://www.dbresearch.com/PROD/RI-PROD/HIDDEn_GLOBAL_SEARCH.alias">wrote</a> on March 13. "This effort cannot be financed within the confines of the debt brake without impacting other core government tasks and thus risking public support."
Merz's CDU and its sister party won the election with 28.6% of the national vote on February 23. He has pledged to form a coalition government in April.
<a href="https://x.com/eurocapinsights/status/1902099051933278522">The economic starting </a>point for the next federal government is extremely challenging, Deutsche Bank Research Institute said. "If the status quo were to persist, German economic growth would likely remain well below 1% per year until the end of the decade."
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Facd1ccf9-10c1-47aa-898b-dcff74a88435_536x565.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Facd1ccf9-10c1-47aa-898b-dcff74a88435_536x565.png" alt="" /></a><figcaption class="wp-element-caption">Source: <a target="_blank" rel="noreferrer noopener" href="https://www.dbresearch.com/PROD/RI-PROD/HIDDEn_GLOBAL_SEARCH.alias">Deutsche Bank Researc</a>h</figcaption></figure>
On Sunday, Germany&#8217;s parliamentary budget committee approved plans to increase state borrowing to bolster defense and revive growth massively.
The committee convened for an extraordinary session and backed the plans &#8212; agreed on Friday between the conservative CDU/CSU, the Social Democrats, and the Greens &#8212; sending them to parliament for adoption.
<h2 class="wp-block-heading">German Economic Sentiment Surges on Fiscal Policy</h2>
Ahead of parliament's vote, German economic sentiment expectation surged to its highest level since January 2023.
The ZEW Indicator of Economic Sentiment for March rose to 51.6 points or 25.6 points above the previous month's reading. The last time the indicator increased this substantially was in January 2023.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4183db1a-8a50-4567-afc8-679f55547faa_670x385.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4183db1a-8a50-4567-afc8-679f55547faa_670x385.png" alt="" /></a></figure>
Source: ZEW
"The brighter mood is likely due to positive signals regarding the future German fiscal policy," including the multi-billion-euro financial package for the federal budget, ZEW President Achim Wambach said on Tuesday. "Prospects for metal and steel manufacturers as well as the mechanical engineering sector have improved"
On March 12, the S&amp;P Global Business Outlook survey showed a slight improvement in the mood among Germany&#8217;s businesses during the first quarter of the year. "Optimism has returned to the country&#8217;s manufacturers," S&amp;P Global said.
"Still, growth forecasts were subdued, amid a backdrop of geopolitical tensions," S&amp;P Global said. Firms predicted sustained strong cost pressures and, as such, cited plans to reduce workforces amid concerns over competitiveness, it said.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd4481913-e74b-47db-b5c3-d75926f099af_363x225.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd4481913-e74b-47db-b5c3-d75926f099af_363x225.png" alt="" /></a><figcaption class="wp-element-caption">Source: <a target="_blank" rel="noreferrer noopener" href="https://www.pmi.spglobal.com/Public/Home/PressRelease/bb1c5aa165bc4067b680586cc39225f1">S&amp;P Global</a></figcaption></figure>
<h2 class="wp-block-heading">Germany Faces Strong Headwinds Despite Fiscal Change</h2>
Germany still faces considerable headwinds. These include, among other things, an aging population, high energy costs, weak productivity, and China&#8217;s emergence as an industrial rival.
Gross domestic product contracted 0.2% in 2024, according to data from the Federal Statistical Office (Destatis). Investments fell by 2.7% in the 4th quarter, compared with the same quarter a year earlier, Destatis said.
Analysts have questioned Germany's commitment to fiscal reform and defense spending. They point to the €100 billion of the €500 billion allocated to climate change rather than increasing power supplies.
"Instead of reopening its nuclear power plants, Germany will vote today to spend another €100 billion for green fairytale projects," Michael A. Arouet, an economy, politics and investing analyst, wrote on <a target="_blank" rel="noreferrer noopener" href="https://x.com/MichaelAArouet/status/1893913497299288311">X</a>. "One could not make it up."
After the parliament's decision, Arouet wrote: "RIP German industry."
Disclaimer:
Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. European Capital Insights is not responsible for any financial decisions made based on the contents of this article. Readers may use this article for information and educational purposes only.&nbsp;
This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Eurozone

Opinion

General

German Parliament Backs Changes to Constitutional 'Debt Brake'

4 analysts have shared their evaluations of Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sabra Health Care REIT, revealing an average target of $18.75, a high estimate of $20.00, and a low estimate of $17.00. Marking an increase of 2.29%, the current average surpasses the previous average price target of $18.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1742335293_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sabra Health Care REIT. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sabra Health Care REIT. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sabra Health Care REIT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sabra Health Care REIT's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Sabra Health Care REIT: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Sabra Health Care REIT showcased positive performance, achieving a revenue growth rate of 11.6% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sabra Health Care REIT's net margin is impressive, surpassing industry averages. With a net margin of 25.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Sabra Health Care REIT's ROE excels beyond industry benchmarks, reaching 1.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.88%, the company showcases effective utilization of assets.
Debt Management: Sabra Health Care REIT's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

SBRA

4 Analysts Assess Sabra Health Care REIT: What You Need To Know

In the latest quarter, 4 analysts provided ratings for Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ocular Therapeutix and provided 12-month price targets. The average target is $16.5, accompanied by a high estimate of $19.00 and a low estimate of $15.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.81%. 
<img src="https://www.benzinga.com/files/images/story/2025/1742335274_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Ocular Therapeutix by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ocular Therapeutix. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Ocular Therapeutix's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ocular Therapeutix's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ocular Therapeutix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Ocular Therapeutix</h2>
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
<h3>Ocular Therapeutix's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Ocular Therapeutix's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.41% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ocular Therapeutix's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -283.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -14.5%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.21%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ocular Therapeutix's debt-to-equity ratio is below the industry average at 0.24, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OCUL

What 4 Analyst Ratings Have To Say About Ocular Therapeutix

During the last three months, 13 analysts shared their evaluations of Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Affirm Holdings and provided 12-month price targets. The average target is $72.31, accompanied by a high estimate of $90.00 and a low estimate of $50.00. Surpassing the previous average price target of $62.77, the current average has increased by 15.2%.
<img src="https://www.benzinga.com/files/images/story/2025/1742335263_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Affirm Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$81.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$85.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Giuliano Bologna</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Affirm Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Affirm Holdings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Affirm Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Affirm Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AFRM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Affirm Holdings analyst ratings.</a>
<h2>Delving into Affirm Holdings's Background</h2>
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.
<h3>Financial Milestones: Affirm Holdings's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Affirm Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 46.57%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Affirm Holdings's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 9.28%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Affirm Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.86%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.78%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.69, Affirm Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFRM

Beyond The Numbers: 13 Analysts Discuss Affirm Holdings Stock

In the last three months, 4 analysts have published ratings on Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $66.5, with a high estimate of $87.00 and a low estimate of $53.00. This upward trend is apparent, with the current average reflecting a 3.91% increase from the previous average price target of $64.00.
<img src="https://www.benzinga.com/files/images/story/2025/1742335254_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Bread Finl Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$58.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$68.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$87.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bread Finl Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bread Finl Hldgs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Bread Finl Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Bread Finl Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BFH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bread Finl Hldgs analyst ratings.</a>
<h2>Delving into Bread Finl Hldgs's Background</h2>
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
<h3>Financial Milestones: Bread Finl Hldgs's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Bread Finl Hldgs's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -9.05%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bread Finl Hldgs's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.76%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Bread Finl Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.23%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Bread Finl Hldgs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.86.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Bread Finl Hldgs Through 4 Analysts

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Teradata, presenting an average target of $30.75, a high estimate of $37.00, and a low estimate of $25.00. Experiencing a 12.77% decline, the current average is now lower than the previous average price target of $35.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1742335242_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Teradata is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$29.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Howard Ma</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Chirag Ved</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teradata. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teradata compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Teradata's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Teradata's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TDC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teradata analyst ratings.</a>
<h2>Unveiling the Story Behind Teradata</h2>
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
<h3>Teradata's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Teradata's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -10.5%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Teradata's ROE excels beyond industry benchmarks, reaching 19.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Teradata's ROA stands out, surpassing industry averages. With an impressive ROA of 1.49%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 4.33, Teradata faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Have This To Say About Teradata

During the last three months, 13 analysts shared their evaluations of Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of $72.00, and a low estimate of $48.00. Marking an increase of 1.67%, the current average surpasses the previous average price target of $65.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1742335223_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Avidity Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avidity Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Avidity Biosciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Avidity Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>Discovering Avidity Biosciences: A Closer Look</h2>
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
<h3>Breaking Down Avidity Biosciences's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Avidity Biosciences's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 35.57%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -3439.52%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -6.98%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.38%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 13 Analyst Projections For Avidity Biosciences

BLNE

Beeline Board Approves Limited Waiver Of Insider Trading Policy; Any Insiders Who Purchase Stock Must Hold For At Least 6 Months

A blockchain project backed by Sam Altman is working to fight off AI bots in video games, one of the latest news pieces since the company rebranded from Worldcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WLD</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41395999/sam-altman-founded-worldcoin-is-changing-its-name-to-world-and-launching-its-own-blockchai">to World Inc.</a>
What Happened: Altman is one of the instrumental people behind the growth of <a href="https://www.benzinga.com/news/23/03/31266515/5-things-you-might-not-know-about-openai-founder-sam-altman-doomsday-prepper-donald-trump-critic-and">helpful AI-like ChatGPT</a> and he may have a new way to fight off artificial intelligence that isn't helpful to video gamers.
World, which Altman co-founded, is partnering with gaming company Razer to launch software that can detect the difference between bots and real gamers, as <a href="https://www.wsj.com/livecoverage/stock-market-today-dow-nasdaq-sp500-03-17-2025/card/new-software-from-sam-altman-backed-world-targets-ai-bots-in-videogames-UxQoickmmqVUcAg2G0A0">reported </a>by the Wall Street Journal.
The newly created Razer ID verified by World ID will give a badge to players detected as real humans as a form of authentication.
"We're on the brink of an AI tsunami. This partnership helps reclaim gaming for human players," Tools for Humanity Chief Business Officer Trevor Traina said.
Tools for Humanity helps develop products for World and helped facilitate the partnership with Razer.
A growing number of bots are participating in games to inflate user numbers or take advantage or in-game economies, according to the report. The growing number of bots can ruin the user experience.
World is best-known for its iris-scanning technology for identity verification, which has created many headlines over the years.
Read Also: <a href="https://www.benzinga.com/25/03/44297444/sam-altman-warns-ai-will-be-deflationary-but-says-openais-biggest-constraint-isnt-data-or-demand-its-gpus">Sam Altman Warns AI Will Be Deflationary, But Says OpenAI&#8217;s Biggest Constraint Isn&#8217;t Data Or Demand, It&#8217;s GPUs</a>
What's Next: The first game to use Razer ID verified by World ID will be "Tokyo Beast," set for a release in the second quarter. The game was developed by CyberAgent.
The sign-in mechanism used by Razer and World ID is built on existing login technology from Razer and will help make sure each Razer ID belongs to a real person, according to Coindesk.
"Game developers now have a tool to build dynamic spaces where real players — not bots — dominate the digital landscape," World said in a statement to <a href="https://www.coindesk.com/tech/2025/03/17/sam-altman-s-world-network-and-razer-want-to-defeat-gaming-s-bot-problem">Coindesk</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44300525/sam-altmans-openai-urges-trump-administration-for-rapid-ai-advancement-and-reduced-regulation">Sam Altman&#8217;s OpenAI Urges Trump Administration For Rapid AI Advancement And Reduced Regulation</a></li>
</ul>
Photo: Shutterstock

Gaming

Tech

$WLD

Sam Altman Wants To Get Rid Of AI Bots In Video Games: Here's The Why And How

Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is a 40 percent increase over earnings of $0.05 per share from the same period last year. The company reported $92.76 million in sales this quarter. This is a 47.48 percent increase over sales of $62.90 million the same period last year.

ORLA

Orla Mining Q4 2024 Adjusted EPS $0.07, Inline, Sales $92.76M Up From $62.90M YoY

BTMD

Biote Says Several Members Of Its Board, Along With CEO Bret Christensen, Made Open Market Purchases Of Aggregate 260,000 Shares

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Comments

Genmab

뉴스

파트너 / 기고자

벤징가 글로벌